Filed with ASX · · 3 pages · English
The ongoing study is randomized and placebo-controlled, evaluating the drug's effects on immune reactions in a model designed to test T-cell responses. Next steps include ongoing analysis of the multiple ascending dose portion of the study, with results expected to inform future Phase II program decisions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses • Statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers, with greater...
